Identification of β-Lactams Active against <i>Mycobacterium tuberculosis</i> by a Consortium of Pharmaceutical Companies and Academic Institutions-Reference-Cited by-同舟云学术

Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions

Published:2022-02-22 Issue:3 Volume:8 Page:557-573
ISSN:2373-8227
Container-title:ACS Infectious Diseases
language:en
Short-container-title:ACS Infect. Dis.

Author:

Gold Ben¹^ORCID,Zhang Jun¹,Quezada Landys Lopez¹,Roberts Julia¹,Ling Yan¹,Wood Madeleine¹,Shinwari Wasima¹,Goullieux Laurent²³,Roubert Christine²³,Fraisse Laurent²,Bacqué Eric²³,Lagrange Sophie²³,Filoche-Rommé Bruno⁴,Vieth Michal⁵,Hipskind Philip A.⁶,Jungheim Louis N.⁷,Aubé Jeffrey⁸,Scarry Sarah M.⁸,McDonald Stacey L.⁸,Li Kelin⁸,Perkowski Andrew⁸,Nguyen Quyen⁸,Dartois Véronique⁹^ORCID,Zimmerman Matthew⁹,Olsen David B.¹⁰,Young Katherine¹⁰,Bonnett Shilah¹¹,Joerss Douglas¹¹,Parish Tanya¹¹^ORCID,Boshoff Helena I.¹²^ORCID,Arora Kriti¹²,Barry Clifton E.¹²,Guijarro Laura¹³,Anca Sara¹³,Rullas Joaquín¹³,Rodríguez-Salguero Beatriz¹³,Martínez-Martínez Maria S.¹³,Porras-De Francisco Esther¹³,Cacho Monica¹³^ORCID,Barros-Aguirre David¹³^ORCID,Smith Paul¹⁴^ORCID,Berthel Steven J.¹⁵,Nathan Carl¹,Bates Robert H.¹³^ORCID

Affiliation:

1. Department of Microbiology & Immunology, Weill Cornell Medicine, 413 East 69th Street, New York, New York 10021, United States

2. Sanofi, Infectious Diseases Therapeutic Area, 69280 Marcy l’Étoile, France

3. Evotec (Lyon) SAS, 69007 Lyon, France

4. Sanofi, Integrated Drug Discovery, 94400 Vitry sur Seine, France

5. Lilly Biotechnology Center, Eli Lilly and Company, 10290 Campus Point Dr, San Diego, California 92121, United States

6. Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana 46285, United States

7. YourEncore, 20 North Meridian Street, Indianapolis, Indiana 46204, United States

8. Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States

9. Public Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey 07103, United States

10. Merck & Co., Inc., Infectious Diseases, 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States

11. TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Ave E, Suite 400, Seattle, Washington 98102, United States

12. Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, Bethesda, Maryland 20892, United States

13. Global Health Pharma R&D, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain

14. Independent Consultant, Global Health Pharma R&D, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, Madrid 28760, Spain

15. Panorama Global, 2101 4th Avenue, Suite 2100, Seattle, Washington 98121, United States

Funder

Division of Intramural Research, National Institute of Allergy and Infectious Diseases

Bill and Melinda Gates Foundation

Abby and Howard P. Milstein Program in Chemical Biology and Translational Medicine

William Randolph Hearst Trust

TB Drug Accelerator Program of the Bill & Melinda Gates Foundation

Publisher

American Chemical Society (ACS)

Subject

Infectious Diseases

Link

https://pubs.acs.org/doi/pdf/10.1021/acsinfecdis.1c00570

Reference73 articles.

1. The challenge of antimicrobial resistance: What economics can contribute

2. Antibiotic Resistance — Problems, Progress, and Prospects

3. Drugs for bad bugs: confronting the challenges of antibacterial discovery

4. Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality

5. Cooperative development of antimicrobials: looking back to look ahead

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utilization of Existing Human Kinase Inhibitors as Scaffolds in the Development of New Antimicrobials;Antibiotics;2023-09-07

2. Randomized control study of the use of faropenem for treating patients with pulmonary tuberculosis;International Journal of Infectious Diseases;2023-07

3. β-Lactams and Ureas as Cross Inhibitors of Prokaryotic Systems;Applied Microbiology;2023-06-25

4. Antibiotics in the clinical pipeline as of December 2022;The Journal of Antibiotics;2023-06-08

5. Mutations in rpoB That Confer Rifampicin Resistance Can Alter Levels of Peptidoglycan Precursors and Affect β-Lactam Susceptibility;mBio;2023-04-25